Skip to main content

AZILECT (Teva Pharma Australia Pty Ltd)

Product name
AZILECT
Date registered
Evaluation commenced
Decision date
Approval time
135 working days (255)
Active ingredients
rasagiline
Registration type
EOI
Indication
AZILECT-RASAGILINE is now also indicated as adjunct therapy to dopamine agonist or to levodovap.

Help us improve the Therapeutic Goods Administration site